Entera Bio (ENTX) Accumulated Expenses (2017 - 2026)

Entera Bio has disclosed Accumulated Expenses across 9 years of filings, most recently posting $1.1 million for Q1 2026.

• Quarterly Accumulated Expenses fell 15.38% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 15.38% YoY) and the FY2025 annual result came in at $1.5 million, up 74.49% from the prior year.
• Accumulated Expenses slipped to $1.1 million in Q1 2026, from $1.5 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $2.0 million in Q1 2022 and troughed at $651000.0 in Q3 2022.
• A 5-year average of $1.2 million and a median of $1.2 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses tumbled 55.98% — and 2023, when it soared 104.61%.
• Tracing ENTX's Accumulated Expenses over 5 years: stood at $1.2 million in 2022, then declined by 29.12% to $874000.0 in 2023, then changed by 0.0% to $874000.0 in 2024, then jumped by 74.49% to $1.5 million in 2025, then declined by 26.75% to $1.1 million in 2026.
• Business Quant data shows ENTX's Accumulated Expenses at $1.1 million in Q1 2026, $1.5 million in Q4 2025, and $1.2 million in Q3 2025.